TrialBritish journal of cancer2006

A phase II study of single-agent gefitinib as first-line therapy in patients with stage IV non-small-cell lung cancer.

R Suzuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.